These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25807939)

  • 1. What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?
    Boers M; Buttgereit F; Saag K; Alten R; Grahn A; Storey D; Rice P; Kirwan J
    Arthritis Care Res (Hoboken); 2015 Sep; 67(9):1202-1209. PubMed ID: 25807939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis.
    Buttgereit F; Kent JD; Holt RJ; Grahn AY; Rice P; Alten R; Yazici Y
    Bull Hosp Jt Dis (2013); 2015 Jul; 73(3):168-77. PubMed ID: 26535595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone.
    Alten R; Holt R; Grahn A; Rice P; Kent J; Buttgereit F; Gibofsky A
    Scand J Rheumatol; 2015; 44(5):354-8. PubMed ID: 26114379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2).
    Buttgereit F; Mehta D; Kirwan J; Szechinski J; Boers M; Alten RE; Supronik J; Szombati I; Romer U; Witte S; Saag KG
    Ann Rheum Dis; 2013 Feb; 72(2):204-10. PubMed ID: 22562974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis.
    Bacci ED; DeLozier AM; Lin CY; Gaich CL; Rooney T; Hoffman R; Wyrwich KW
    Health Qual Life Outcomes; 2017 Dec; 15(1):239. PubMed ID: 29212515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity.
    Ward MM; Guthrie LC; Dasgupta A
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):323-329. PubMed ID: 27273981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should morning function in rheumatoid arthritis be assessed? Bibliographic study of current assessment.
    Cutolo M
    Scand J Rheumatol Suppl; 2011; 125():17-22. PubMed ID: 21529306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching From Immediate-Release to Delayed-Release Prednisone in Moderate to Severe Rheumatoid Arthritis: A Practice-Based Clinical Study.
    Dikranian AH; Mallay R; Marshall M; Francis-Sedlak M; Holt RJ
    Rheumatol Ther; 2017 Dec; 4(2):363-374. PubMed ID: 28819927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity.
    Khan NA; Yazici Y; Calvo-Alen J; Dadoniene J; Gossec L; Hansen TM; Huisman M; Kallikorm R; Muller R; Liveborn M; Oding R; Luchikhina E; Naranjo A; Rexhepi S; Taylor P; Tlustochowich W; Tsirogianni A; Sokka T;
    J Rheumatol; 2009 Nov; 36(11):2435-42. PubMed ID: 19833759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Lancet; 2008 Jan; 371(9608):205-14. PubMed ID: 18207016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Old But Good: Modified-Release Prednisone in Rheumatoid Arthritis.
    Ursini F; Naty S; Bruno C; Grembiale RD
    Rev Recent Clin Trials; 2017; 12(2):124-128. PubMed ID: 28356031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A reevaluation of the symptom of morning stiffness.
    Hazes JM; Hayton R; Silman AJ
    J Rheumatol; 1993 Jul; 20(7):1138-42. PubMed ID: 8371206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis.
    Buttgereit F; Doering G; Schaeffler A; Witte S; Sierakowski S; Gromnica-Ihle E; Jeka S; Krueger K; Szechinski J; Alten R
    Ann Rheum Dis; 2010 Jul; 69(7):1275-80. PubMed ID: 20542963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified-release prednisone: in patients with rheumatoid arthritis.
    Henness S; Yang LP
    Drugs; 2013 Dec; 73(18):2067-76. PubMed ID: 24249648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More than Just Minutes of Stiffness in the Morning: Report from the OMERACT Rheumatoid Arthritis Flare Group Stiffness Breakout Sessions.
    Orbai AM; Halls S; Hewlett S; Bartlett SJ; Leong AL; Bingham CO;
    J Rheumatol; 2015 Nov; 42(11):2182-4. PubMed ID: 25729035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis.
    Ranzolin A; Brenol JC; Bredemeier M; Guarienti J; Rizzatti M; Feldman D; Xavier RM
    Arthritis Rheum; 2009 Jun; 61(6):794-800. PubMed ID: 19479706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease.
    Sierakowski S; Cutolo M
    Scand J Rheumatol Suppl; 2011; 125():1-5. PubMed ID: 21529303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
    Bingham CO; Gaich CL; DeLozier AM; Engstrom KD; Naegeli AN; de Bono S; Banerjee P; Taylor PC
    Trials; 2019 Mar; 20(1):182. PubMed ID: 30902094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.